Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
24.76
-0.55 (-2.17%)
At close: Nov 3, 2025, 4:00 PM EST
25.24
+0.48 (1.94%)
After-hours: Nov 3, 2025, 5:18 PM EST
Arcutis Biotherapeutics Revenue
Arcutis Biotherapeutics had revenue of $99.22M in the quarter ending September 30, 2025, with 121.69% growth. This brings the company's revenue in the last twelve months to $317.93M, up 129.21% year-over-year. In the year 2024, Arcutis Biotherapeutics had annual revenue of $196.54M with 229.74% growth.
Revenue (ttm)
$317.93M
Revenue Growth
+129.21%
P/S Ratio
10.06
Revenue / Employee
$929,617
Employees
342
Market Cap
3.03B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 196.54M | 136.94M | 229.74% |
| Dec 31, 2023 | 59.61M | 55.92M | 1,517.09% |
| Dec 31, 2022 | 3.69M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
ARQT News
- 4 days ago - Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments - GlobeNewsWire
- 4 days ago - Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5 - GlobeNewsWire
- 5 days ago - Arcutis' Q3 Earnings: Increased Foam Share, Better GTN, And Clear 2026 Guide Made Share Rally - Seeking Alpha
- 6 days ago - Arcutis Biotherapeutics, Inc. (ARQT) Analyst/Investor Day Transcript - Seeking Alpha
- 6 days ago - Arcutis Biotherapeutics: Soaring On Q3 Earnings - Further Upside Likely (Upgrade) - Seeking Alpha
- 6 days ago - Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results - GlobeNewsWire
- 7 days ago - Arcutis to Present at Upcoming Investor Conferences - GlobeNewsWire
- 10 days ago - Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference - GlobeNewsWire